Asahi Kasei in Hot Pursuit of Eli Lilly Japan as Competition Heats Up in Market for Bone Formation Agents

Eli Lilly Japan and Asahi Kasei Pharma are engaged in fierce competition in the field of bone formation agents, a new category of osteoporosis treatment. Eli Lilly Japan’s Forteo (teriparatide) made its debut as the first bone formation agent in...read more